Inclusion Criteria

- INCLUSION CRITERIA:

1. Males and females between the ages of 18 and 60 years.

2. Healthy by medical history and physical exam

3. Laboratory values within established guidelines for participation in clinical
studies: AST less than or equal to 2 times ULN (upper limit of normal); Serum
creatinine less than or equal to ULN; hemoglobin greater than or equal to 11
g/dL.

4. Ability to abstain from ingesting grapefruit or grapefruit juice 72 hours prior
to, and the days of midazolam phenotyping and indinavir and saquinavir
administration.

5. Negative serum pregnancy test for females of child-bearing potential.

6. Females of child-bearing potential are able and willing to practice abstinence
or use other effective methods of birth control during Phase II of study that do
not include oral contraceptives.

EXCLUSION CRITERIA:

1. Concomitant routine therapy with any prescription, over the counter, herbal, or
holistic medications, including oral contraceptives for 30 days prior to study
participation.

- Subjects must be off oral contraceptives for at least 30 days prior to blood
collection for P-gp expression analysis; they must also be off oral
contraceptives for at least 30 days prior to midazolam phenotyping, and
indinavir and saquinavir administration.

- Intermittent (PRN) use of acetaminophen and non-steroidal anti-inflammatory
medications (i.e. ibuprofen) will be allowed during the study; these medications
should not be taken prior to, or within 4 hours of midazolam administration on
Day 0. These medications should not be taken during indinavir and saquinavir
administration until all blood samples for pharmacokinetic analyses of the
respective drugs have been obtained.

- Subjects will be allowed to take a multivitamin with minerals, or equivalent,
once daily if they desire to do so.

2. Inability to obtain venous access for sample collection.

3. Presence of Diabetes mellitus, Human immunodeficiency virus (HIV) infection, cardiac
disease (hypertension; congestive heart failure etc.), renal disease (chronic or
acute renal failure or insufficiency), respiratory disease (asthma requiring chronic
treatment; chronic obstructive pulmonary disease) or any other condition that may
interfere with the interpretation of the study results or not be in the best interest
of the subject in the opinion of the investigator.

4. Positive pregnancy test or breastfeeding female.

5. The presence of persistent diarrhea or malabsorption that would interfere with the
subject's ability to absorb drugs.

6. Drug or alcohol use that may impair safety or adherence.

7. History of intolerance or allergic reaction (rash; hives; swollen lips; difficulty
breathing) to indinavir, saquinavir or midazolam.

8. Inability or unwillingness of females of child-bearing potential, to use a
non-hormonal (barrier) method of contraception throughout the study (e.g. condom
diaphragm etc.).

9. Current cigarette smoker or regular smoker within the past 6 weeks.